Abstracts tagged "hyperuricemia"

Abstract Number: 1121 • 2017 ACR/ARHP Annual Meeting
Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?
Jean J. Lim^1,2, An-Chen Fu², Jami Giordano², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Urate-lowering therapy (ULT) is essential in chronic gout management. For decades, allopurinol has remained the most frequently prescribed ULT. Reaching a goal of serum…
Abstract Number: 1122 • 2017 ACR/ARHP Annual Meeting
Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012
Jean J. Lim^1,2, An-Chen Fu², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis, mainly caused by elevated serum uric acid (sUA) levels. The American College of Rheumatology guidelines…
Abstract Number: 2081 • 2017 ACR/ARHP Annual Meeting
Synovial Fluid Leukocyte Count and Its Association with Crystal Deposition in Asymptomatic Hyperuricemia
Mariano Andrés^1,2, José Antonio Bernal³, María Dolores Arenas⁴ and Eliseo Pascual^1,5, ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ³Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ⁴Unidad de Nefrología, Hospital Vithas Perpetuo Socorro, Alicante, Spain, ⁵Emeritus Professor, Universidad Miguel Hernández, Elche, Spain
Background/Purpose: Articular and periarticular deposits of monosodium urate (MSU) crystals in asymptomatic hyperuricemia (AH) may associate with more severe forms of atherosclerosis [Andrés 2016]. This…
Abstract Number: 196 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study
Roy Fleischmann¹, Peter Winkle², Jesse Hall³, Xiaohong Yan³, Jeffrey N. Miner^3,4, Liz Hicks³, Shakti Valdez³ and Martha Hernandez-Illas⁵, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Anaheim Clinical Trials, Anaheim, CT, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ⁵QPS MRA (Miami Clinical Research), Miami, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…
Abstract Number: 197 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study
Roy Fleischmann¹, Peter Winkle², Jesse Hall³, Shakti Valdez³, Sha Liu³, Xiaohong Yan³, Liz Hicks³ and Martha Hernandez-Illas⁴, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Anaheim Clinical Trials, Anaheim, CT, ³Ardea Biosciences, Inc., San Diego, CA, ⁴QPS MRA (Miami Clinical Research), Miami, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…
Abstract Number: 229 • 2016 ACR/ARHP Annual Meeting
Relationship Between Patient and Disease Factors and Severity of Gout in a Real-World Population
Michael Pillinger¹, Svetlana Krasnokutsky Samuels¹, Raymond Malamet², Bruce Schechter², Douglas CA Taylor³ and Robert Morlock⁴, ¹New York University, New York, NY, ²AstraZeneca, Gaithersburg, MD, ³Ironwood Pharmaceuticals, Cambridge, MA, ⁴Ardea Biosciences, Inc., San Diego, CA
Background/Purpose : Gout is the most prominent clinical manifestation of hyperuricemia, and is the most common cause of inflammatory arthritis. The symptoms of gout (eg,…
Abstract Number: 2268 • 2016 ACR/ARHP Annual Meeting
Fructose Amplifies Inflammatory Potential in Human Monocytic Cells Via Reduction of AMP-Activated Protein Kinase Activity
Xihua Cao¹, Jeffrey N. Miner², Robert Terkeltaub^3,4 and Ru Liu-Bryan^1,4, ¹VA Medical Center, San Diego, CA, ²Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ³Rheumatology, VA Medical Center, San Diego, CA, ⁴Medicine-Rheumatology, University of California, San Diego, La Jolla, CA
Background/Purpose: High dietary content of fructose (in table sugar, sweetened sodas, energy beverages, and fruit juices) is a substantial risk factor for both hyperuricemia and…
Abstract Number: 2293 • 2016 ACR/ARHP Annual Meeting
Cardiometabolic Risk and Subclinical Urate Deposits in Patients with Symptomatic Hyperuricemia and Metabolic Syndrome
Seoyoung C. Kim¹, Rajesh Garg², Stacy Smith³, Alyssa Wohlfahrt⁴, Anarosa Campos⁵, Kathleen Vanni⁴, Lauren K Lee⁶, Penny Wang⁶, Zhi Yu⁷, Marcelo Di Carli⁸ and Daniel H. Solomon⁹, ¹Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ²Endocrinology, Brigham & Women's Hospital, Boston, MA, ³Radiology/Division of Musculoskeletal Imaging & Intervention, Brigham & Women's Hospital/ Harvard Medical School, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ⁸Div. of Nuclear Medicine, Brigham and Women's Hospital, Boston, MA, ⁹Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Elevated serum uric acid (sUA) levels, with and without gout, are associated with systemic inflammation, coronary artery disease (CAD), chronic kidney disease, and diabetes.…
Abstract Number: 2297 • 2016 ACR/ARHP Annual Meeting
Serum Urate and Its Association with Race in Young Adults: Baseline Analysis from a Randomized Clinical Trial
Michael B. Saddekni¹, Angelo L. Gaffo¹, Phillip J. Foster¹, Elizabeth J. Rahn¹, Stephanie R. Biggers¹, Peng Li² and Kenneth G. Saag¹, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Increased levels of serum urate (sUA) have been reported in association with hypertension, chronic kidney disease, and obesity. All these conditions are over-represented in…
Abstract Number: 190 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects
Michael Gillen¹, Zangong Shen² and Jeffrey N. Miner³, ¹AstraZeneca, Gaithersburg, MD, ²Ardea Biosciences, San Diego, CA, ³Discovery Biology, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: This was a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study. Panels of 8 male subjects (6 active, 2 placebo) received a…
Abstract Number: 191 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Febuxostat in Healthy Adult Male Subjects
James VanderLugt¹, Michael Gillen², Xiaojuan Yang³ and Jesse Hall³, ¹Jasper Clinical Research & Development, Kalamazoo, MI, ²AstraZeneca, Gaithersburg, MD, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1,…
Abstract Number: 192 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study
William B Smith¹, Jesse Hall², Jolene Berg³, Michal Kazimir⁴, Amy Yamamoto², Caroline Lee², Susan Walker² and Thomas C. Marbury⁵, ¹Volunteer Research Group, Knoxville, TN, ²Ardea Biosciences, Inc., San Diego, CA, ³DaVita Clinical Research, Minneapolis, MN, ⁴DaVita Clinical Research, Lakewood, CO, ⁵Orlando Clinical Research Center, Orlando, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1, single-dose, open-label study…
Abstract Number: 193 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese Male Subjects
Michael Gillen¹, Jeffrey N. Miner² and Shakti Valdez³, ¹AstraZeneca, Gaithersburg, MD, ²Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: This was a Phase 1, randomized, single-blind, placebo-controlled study (. Panels of 8 Japanese male subjects were randomized in a 3:1 ratio to receive…
Abstract Number: 194 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout
Jesse Hall¹, Michael Gillen², Xiaojuan Yang¹, Sha Liu¹, Susan Walker¹, Vicki Clauson¹ and Martin Kankam³, ¹Ardea Biosciences, Inc., San Diego, CA, ²AstraZeneca, Gaithersburg, MD, ³Vince and Associates Clinical Research, Inc.,, Overland Park, KS
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of hyperuricemia and gout. This Phase 1, single-blind,…
Abstract Number: 195 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study
Masanari Shiramoto¹, Masatoshi Sugeno², Sha Liu³, Zangong Shen³ and Jesse Hall³, ¹SOUSEIKAI PS Clinic, Fukuoka, Japan, ²AstraZeneca K.K., Osaka, Japan, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Verinurad (RDEA3170) is a high-affinity URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, single-site study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].